TransCode Therapeutics (RNAZ) Competitors $9.88 -0.17 (-1.69%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$10.11 +0.23 (+2.33%) As of 08/28/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNAZ vs. MRSN, SCYX, RNXT, ALXO, OKUR, ESLA, CLSD, BTAI, AKTX, and SNYRShould you be buying TransCode Therapeutics stock or one of its competitors? The main competitors of TransCode Therapeutics include Mersana Therapeutics (MRSN), SCYNEXIS (SCYX), RenovoRx (RNXT), ALX Oncology (ALXO), OnKure Therapeutics (OKUR), Estrella Immunopharma (ESLA), Clearside Biomedical (CLSD), BioXcel Therapeutics (BTAI), Akari Therapeutics (AKTX), and Synergy CHC (SNYR). These companies are all part of the "pharmaceutical products" industry. TransCode Therapeutics vs. Its Competitors Mersana Therapeutics SCYNEXIS RenovoRx ALX Oncology OnKure Therapeutics Estrella Immunopharma Clearside Biomedical BioXcel Therapeutics Akari Therapeutics Synergy CHC Mersana Therapeutics (NASDAQ:MRSN) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations. Does the media refer more to MRSN or RNAZ? In the previous week, Mersana Therapeutics had 1 more articles in the media than TransCode Therapeutics. MarketBeat recorded 2 mentions for Mersana Therapeutics and 1 mentions for TransCode Therapeutics. TransCode Therapeutics' average media sentiment score of 1.87 beat Mersana Therapeutics' score of 0.96 indicating that TransCode Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Mersana Therapeutics Positive TransCode Therapeutics Very Positive Do analysts prefer MRSN or RNAZ? Mersana Therapeutics presently has a consensus price target of $56.60, indicating a potential upside of 638.90%. TransCode Therapeutics has a consensus price target of $280.00, indicating a potential upside of 2,734.01%. Given TransCode Therapeutics' higher probable upside, analysts clearly believe TransCode Therapeutics is more favorable than Mersana Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mersana Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00TransCode Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings and valuation, MRSN or RNAZ? TransCode Therapeutics has lower revenue, but higher earnings than Mersana Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMersana Therapeutics$40.50M0.94-$69.19M-$14.62-0.52TransCode TherapeuticsN/AN/A-$16.75MN/AN/A Is MRSN or RNAZ more profitable? TransCode Therapeutics has a net margin of 0.00% compared to Mersana Therapeutics' net margin of -212.94%. TransCode Therapeutics' return on equity of -378.30% beat Mersana Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mersana Therapeutics-212.94% -990.16% -54.85% TransCode Therapeutics N/A -378.30%-186.01% Do institutionals and insiders believe in MRSN or RNAZ? 93.9% of Mersana Therapeutics shares are held by institutional investors. 13.0% of Mersana Therapeutics shares are held by company insiders. Comparatively, 0.0% of TransCode Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more volatility and risk, MRSN or RNAZ? Mersana Therapeutics has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, TransCode Therapeutics has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500. SummaryMersana Therapeutics and TransCode Therapeutics tied by winning 6 of the 12 factors compared between the two stocks. Get TransCode Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNAZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNAZ vs. The Competition Export to ExcelMetricTransCode TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.38M$2.51B$5.78B$9.79BDividend YieldN/A1.68%3.95%4.02%P/E RatioN/A22.8231.2726.59Price / SalesN/A547.03428.42155.72Price / CashN/A177.0937.7359.36Price / Book1.346.1810.046.68Net Income-$16.75M$32.94M$3.27B$265.59M7 Day Performance-3.70%-0.78%1.34%0.66%1 Month Performance-15.99%2.77%6.13%2.64%1 Year Performance-99.88%12.01%41.90%22.36% TransCode Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNAZTransCode Therapeutics1.9967 of 5 stars$9.88-1.7%$280.00+2,734.0%-99.9%$8.38MN/A0.009Positive NewsMRSNMersana Therapeutics4.1564 of 5 stars$7.38+3.1%$56.60+666.9%-79.4%$35.73M$34.77M-0.50150SCYXSCYNEXIS1.1684 of 5 stars$0.80-4.5%N/A-42.0%$35.21M$3.75M-2.0160RNXTRenovoRx3.1175 of 5 stars$0.94-1.6%$7.25+671.3%-5.2%$34.94M$40K-2.476Gap UpALXOALX Oncology3.1996 of 5 stars$0.97+50.7%$3.30+239.9%-51.3%$34.50MN/A-0.4440Gap UpHigh Trading VolumeOKUROnKure Therapeutics2.9099 of 5 stars$2.80+10.7%$32.33+1,054.8%N/A$34.18MN/A-0.58N/ATrending NewsAnalyst ForecastAnalyst RevisionESLAEstrella Immunopharma3.1362 of 5 stars$0.92+1.0%$16.00+1,640.1%-18.6%$33.73MN/A-3.54N/APositive NewsCLSDClearside Biomedical2.6799 of 5 stars$0.43+0.7%$4.20+886.1%-61.3%$33.21M$1.66M-1.1530Positive NewsBTAIBioXcel Therapeutics4.5148 of 5 stars$5.67+3.5%$39.75+601.1%-57.6%$33.19M$2.27M-0.4590Trending NewsAnalyst DowngradeAKTXAkari Therapeutics3.0617 of 5 stars$1.00-1.0%$5.00+400.0%-78.8%$32.50MN/A0.009Positive NewsSNYRSynergy CHC4.3726 of 5 stars$3.48+1.5%$10.00+187.4%N/A$31.54M$33.70M9.1640 Related Companies and Tools Related Companies Mersana Therapeutics Competitors SCYNEXIS Competitors RenovoRx Competitors ALX Oncology Competitors OnKure Therapeutics Competitors Estrella Immunopharma Competitors Clearside Biomedical Competitors BioXcel Therapeutics Competitors Akari Therapeutics Competitors Synergy CHC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNAZ) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransCode Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access